(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are Alnylam Pharmaceuticals, Coinbase, and Everbridge.

Rank Financial Asset Price Change Updated (EST)
1 Alnylam Pharmaceuticals (ALNY) 211.79 49.18% 2022-08-03 14:55:08
2 Coinbase (COIN) 81.05 20.56% 2022-08-03 14:55:06
3 Everbridge (EVBG) 32.58 16.4% 2022-08-03 14:54:44
4 Moderna (MRNA) 186.69 16.09% 2022-08-03 14:49:45
5 Globalstar (GSAT) 1.62 15.71% 2022-08-03 14:54:32
6 Unum Group (UNM) 35.96 14.65% 2022-08-03 14:52:39
7 Cemtrex (CETXP) 0.98 13.99% 2022-08-02 21:13:06
8 Evofem Biosciences (EVFM) 0.87 13.74% 2022-08-03 15:08:06
9 Wayfair (W) 64.81 12.81% 2022-08-03 14:53:00
10 Square (SQ) 88.39 11.76% 2022-08-03 14:54:04

The three most active and biggest losers today are Citius Pharmaceuticals, Check-Cap Ltd., and Daseke.

Rank Financial Asset Price Change Updated (EST)
1 Citius Pharmaceuticals (CTXRW) 0.02 -58.44% 2022-08-03 05:06:11
2 Check-Cap Ltd. (CHEKZ) 0.05 -37.38% 2022-08-02 22:41:12
3 Daseke (DSKE) 6.97 -18.95% 2022-08-03 07:48:16
4 Horizon Therapeutics (HZNP) 67.01 -18.41% 2022-08-03 14:58:49
5 Match Group (MTCH) 63.19 -17.63% 2022-08-03 14:49:48
6 Merrimack Pharmaceuticals (MACK) 4.30 -13.65% 2022-08-03 14:59:39
7 Novo Nordisk A/S (NVO) 100.03 -12.61% 2022-08-03 14:57:24
8 STERIS (STE) 203.65 -9.26% 2022-08-03 14:58:28
9 Charles River Laboratories (CRL) 222.60 -8.64% 2022-08-03 14:53:53
10 TherapeuticsMD (TXMD) 8.69 -8.1% 2022-08-03 14:51:06

Most Active Winners today

1. Alnylam Pharmaceuticals (ALNY) – 49.18%

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical firm that focuses on the discovery, development, and commercialization of RNA interference therapeutics. Its investigational RNAi therapeutics are focused on gene medicines, cardio-metabolic disorders, central nervous system/ocular disease, and genetic medicine. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). The company also develops givosiran to treat patients with AHP, lumasiran to treat primary hyperoxaluria, or PH1, and patisiran to treat transthyretinosis or ATTR, amyloidosis with cardiomyopathy. Alnylam Pharmaceuticals, Inc. is a member of several strategic alliances, including with Sanofi Genzyme, The Medicines Company, Ionis Pharmaceuticals, Inc., and Regeneron Pharmaceuticals, Inc., in addition to Vir Biotechnology, Inc., for the development of RNAi therapeutics that can be used to treat coronavirus infections, COVID-19, etc. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. It was established in 2002. The company is located in Cambridge, Massachusetts.

NASDAQ ended the session with Alnylam Pharmaceuticals rising 49.18% to $211.79 on Wednesday, following the last session’s upward trend. NASDAQ jumped 2.59% to $12,668.16, after two successive sessions in a row of losses, on what was an all-around bullish trend exchanging session today.

Volume

Today’s last reported volume for Alnylam Pharmaceuticals is 8030120 which is 898.72% above its average volume of 804037.

Alnylam Pharmaceuticals’s last close was $141.97, 33.03% below its 52-week high of $212.00.

Alnylam Pharmaceuticals’s Sales

Alnylam Pharmaceuticals’s sales growth is 31.6% for the present quarter and 28.6% for the next.

Alnylam Pharmaceuticals’s Revenue

Year-on-year quarterly revenue growth grew by 1.9%, now sitting on 884.24M for the twelve trailing months.

Alnylam Pharmaceuticals’s Stock Yearly Top and Bottom Value

Alnylam Pharmaceuticals’s stock is valued at $211.79 at 17:32 EST, below its 52-week high of $212.00 and way higher than its 52-week low of $117.58.

Alnylam Pharmaceuticals’s Moving Average

Alnylam Pharmaceuticals’s worth is way higher than its 50-day moving average of $138.76 and way higher than its 200-day moving average of $157.22.

More news about Alnylam Pharmaceuticals.

2. Coinbase (COIN) – 20.56%

NASDAQ ended the session with Coinbase jumping 20.56% to $81.05 on Wednesday, after two consecutive sessions in a row of gains. NASDAQ rose 2.59% to $12,668.16, after two successive sessions in a row of losses, on what was an all-around up trend exchanging session today.

Volume

Today’s last reported volume for Coinbase is 23762600 which is 46.87% above its average volume of 16179100.

Coinbase’s last close was $67.23, 81.78% under its 52-week high of $368.90.

The company’s growth estimates for the present quarter and the next is a negative 97.7% and a negative 101.2%, respectively.

Coinbase’s Revenue

Year-on-year quarterly revenue growth grew by 327.1%, now sitting on 7.84B for the twelve trailing months.

Coinbase’s Stock Yearly Top and Bottom Value

Coinbase’s stock is valued at $81.05 at 17:32 EST, way below its 52-week high of $368.90 and way above its 52-week low of $40.83.

Coinbase’s Moving Average

Coinbase’s value is way below its 50-day moving average of $107.90 and way below its 200-day moving average of $210.61.

More news about Coinbase.

3. Everbridge (EVBG) – 16.4%

Everbridge, Inc. is a US-based software company. The company’s software-as-a-service platform, Critical Event Management, includes several software applications. These include Mass Notification, which allows organizations and government agencies to notify individuals and groups based on their last known location; Safety Connection, which allows organizations to send notification messages to individual or group members; Incident Management that allows organizations to streamline workflows and makes communications more relevant; and IT Alerting, which enables IT professionals and IT personnel to communicate and alert during an IT outage or incident. Visual Command Center allows customers to integrate threat data and information about internal incidents. It also offers Public Warning that can reach international mobile population. Risk Center solutions that allow organizations to aggregate data and give incident information and analysis. Crisis Management provides mobile access for crisis management, brand protection, and recovery. Secure Collaboration is a way to share messages, voice and images. Control Center applications are used to manage mission-critical controls. The company also offers customer support. The company serves small and medium-sized businesses as well as non-profit and educational organizations. It also provides support services for government agencies. In April 2009, the company changed its name from 3n Global, Inc. to Everbridge, Inc. It was established in 2002. The headquarters are located in Burlington in Massachusetts.

NASDAQ ended the session with Everbridge rising 16.4% to $32.58 on Wednesday, after two successive sessions in a row of gains. NASDAQ rose 2.59% to $12,668.16, after two sequential sessions in a row of losses, on what was an all-around bullish trend trading session today.

Volume

Today’s last reported volume for Everbridge is 673395 which is 17.37% below its average volume of 815012.

Everbridge’s last close was $27.99, 83.28% under its 52-week high of $167.40.

The company’s growth estimates for the present quarter is a negative 500% and positive 160% for the next.

Everbridge’s Revenue

Year-on-year quarterly revenue growth grew by 36%, now sitting on 368.43M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Everbridge’s stock is considered to be oversold (<=20).

Everbridge’s Stock Yearly Top and Bottom Value

Everbridge’s stock is valued at $32.58 at 17:32 EST, way below its 52-week high of $167.40 and way above its 52-week low of $24.68.

Everbridge’s Moving Average

Everbridge’s worth is below its 50-day moving average of $32.63 and way below its 200-day moving average of $62.89.

More news about Everbridge.

4. Moderna (MRNA) – 16.09%

NASDAQ ended the session with Moderna rising 16.09% to $186.69 on Wednesday while NASDAQ jumped 2.59% to $12,668.16.

Volume

Today’s last reported volume for Moderna is 12676200 which is 129.68% above its average volume of 5518960.

Moderna’s last close was $160.81, 67.68% below its 52-week high of $497.49.

Moderna’s Sales

Moderna’s sales growth is a negative 2.9% for the present quarter and a decline by 3.1% for the next. The company’s growth estimates for the present quarter and the next is a negative 26.6% and a negative 6.5%, respectively.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 1162.9%, now sitting on 18.47B for the twelve trailing months.

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $186.69 at 17:32 EST, way below its 52-week high of $497.49 and way above its 52-week low of $115.61.

Moderna’s Moving Average

Moderna’s worth is way higher than its 50-day moving average of $145.31 and under its 200-day moving average of $197.52.

More news about Moderna.

5. Globalstar (GSAT) – 15.71%

NYSE ended the session with Globalstar rising 15.71% to $1.62 on Wednesday while NYSE jumped 0.69% to $15,267.16.

Volume

Today’s last reported volume for Globalstar is 12959000 which is 261.58% above its average volume of 3583940.

Globalstar’s Sales

Globalstar’s sales growth is a negative 13.3% for the current quarter and a decline by 13.7% for the next.

More news about Globalstar.

6. Unum Group (UNM) – 14.65%

Unum Group and its affiliates offer financial protection benefits solutions throughout the United States, United Kingdom, Poland, as well as internationally. The company operates via Unum US and Unum International segments. Colonial Life and Closed Block are its subsidiaries. It offers group short-term and long-term disability, group live, and accidental loss and dismemberment products. The company also provides supplemental products such as dental and vision, individual disability and benefits and supplemental products like voluntary benefits and voluntary benefits. The company also offers group life, individual and corporate-owned insurances, as well as reinsurance pools, management operations and other products. It sells products to employees primarily through employers. Unum Group’s products are sold through independent brokers and independent contractors, field sales staff, consultants, and independent agency sales representatives. It was established in Chattanooga in Tennessee in 1848.

NYSE ended the session with Unum Group jumping 14.65% to $35.96 on Wednesday while NYSE rose 0.69% to $15,267.16.

Volume

Today’s last reported volume for Unum Group is 2733520 which is 29.77% above its average volume of 2106280.

Unum Group’s last close was $31.36, 16.35% below its 52-week high of $37.49.

Unum Group’s Sales

Unum Group’s sales growth is 1.8% for the current quarter and 1.5% for the next. The company’s growth estimates for the ongoing quarter is a negative 16.5% and positive 23.5% for the next.

Unum Group’s Revenue

Year-on-year quarterly revenue growth declined by 30.3%, now sitting on 12.01B for the twelve trailing months.

Unum Group’s Stock Yearly Top and Bottom Value

Unum Group’s stock is valued at $35.96 at 17:32 EST, under its 52-week high of $37.49 and way higher than its 52-week low of $22.25.

Unum Group’s Moving Average

Unum Group’s value is above its 50-day moving average of $34.28 and way higher than its 200-day moving average of $28.86.

More news about Unum Group.

7. Cemtrex (CETXP) – 13.99%

Cemtrex, Inc. is a US-based technology company. Two segments of the company are Advanced Technologies and Industrial Services. Advanced Technologies provides Internet of Things products, smart devices, under SmartDesk, for mobile, web and virtual augmented reality. It also offers security and surveillance solutions. The segment offers web-based video surveillance systems as well as analytics-based recognition and cameras. It also provides access control systems to secure and monitor industrial and commercial buildings, federal prisons and hospitals, schools, universities, schools, and other federal or state offices. Industrial Services provides single-source solutions for in-plant maintenance, rigging and equipment relocation. It also installs precision machinery in various markets including automotive, printing and graphics and chemical. The firm was previously known as Diversified American Holding, Inc., but changed its name in December 2004 to Cemtrex, Inc. Cemtrex, Inc. is an American company that was founded in 1998. Its headquarters are in Brooklyn, New York.

NASDAQ ended the session with Cemtrex rising 13.99% to $0.98 on Wednesday while NASDAQ rose 2.59% to $12,668.16.

Volume

Today’s last reported volume for Cemtrex is 1600 which is 96.69% below its average volume of 48403.

Cemtrex’s last close was $0.98, 73.66% under its 52-week high of $3.72.

Cemtrex’s Revenue

Year-on-year quarterly revenue growth grew by 37.4%, now sitting on 48.44M for the twelve trailing months.

Cemtrex’s Stock Yearly Top and Bottom Value

Cemtrex’s stock is valued at $0.98 at 17:32 EST, way below its 52-week high of $3.72 and way higher than its 52-week low of $0.60.

Cemtrex’s Moving Average

Cemtrex’s value is below its 50-day moving average of $1.04 and way below its 200-day moving average of $1.56.

More news about Cemtrex.

8. Evofem Biosciences (EVFM) – 13.74%

Evofem Biosciences, Inc., is a biopharmaceutical firm that develops and markets products for women’s reproductive and sexual health. Phexxi is a vaginal cream for prevention of pregnancies. EVO100 is an antimicrobial vaginal cream that prevents urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae infections in women. To educate the oncology community regarding Phexxi, it has entered into a partnership agreement with National Community Oncology Dispensing Association, Inc. Evofem Biosciences, Inc., is located in San Diego, California.

NASDAQ ended the session with Evofem Biosciences rising 13.74% to $0.87 on Wednesday, following the last session’s downward trend. NASDAQ rose 2.59% to $12,668.16, after two sequential sessions in a row of losses, on what was an all-around positive trend exchanging session today.

Volume

Today’s last reported volume for Evofem Biosciences is 16260200 which is 51.29% below its average volume of 33384800.

Evofem Biosciences’s last close was $0.77, 94.76% under its 52-week high of $14.61.

Evofem Biosciences’s Sales

Evofem Biosciences’s sales growth is 225.8% for the present quarter and 165.5% for the next. The company’s growth estimates for the ongoing quarter and the next is 76.3% and 92.2%, respectively.

Evofem Biosciences’s Revenue

Year-on-year quarterly revenue growth grew by 284.7%, now sitting on 11.39M for the twelve trailing months.

Evofem Biosciences’s Stock Yearly Top and Bottom Value

Evofem Biosciences’s stock is valued at $0.87 at 17:33 EST, way under its 52-week high of $14.61 and way above its 52-week low of $0.28.

Evofem Biosciences’s Moving Average

Evofem Biosciences’s worth is way higher than its 50-day moving average of $0.68 and way under its 200-day moving average of $4.73.

More news about Evofem Biosciences.

9. Wayfair (W) – 12.81%

Wayfair Inc. is an e-commerce company that operates in the United States as well internationally. The company offers approximately 18 million home goods under different brands. It offers a variety of furniture and dA (c)cor products, as well as decorative accents and housewares. Wayfair Inc. was established in 2002. It is located in Boston, Massachusetts.

NYSE ended the session with Wayfair jumping 12.81% to $64.81 on Wednesday, after five sequential sessions in a row of gains. NYSE rose 0.69% to $15,267.16, after two sequential sessions in a row of losses, on what was a somewhat positive trend exchanging session today.

Volume

Today’s last reported volume for Wayfair is 4911370 which is 21.47% above its average volume of 4043000.

Wayfair’s last close was $57.45, 81.9% below its 52-week high of $317.45.

The company’s growth estimates for the ongoing quarter and the next is a negative 196.8% and a negative 1200%, respectively.

Wayfair’s Revenue

Year-on-year quarterly revenue growth declined by 11.4%, now sitting on 13.71B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Wayfair’s stock is considered to be oversold (<=20).

Wayfair’s Stock Yearly Top and Bottom Value

Wayfair’s stock is valued at $64.81 at 17:33 EST, way below its 52-week high of $317.45 and way above its 52-week low of $43.31.

Wayfair’s Moving Average

Wayfair’s worth is above its 50-day moving average of $59.55 and way below its 200-day moving average of $156.38.

More news about Wayfair.

10. Square (SQ) – 11.76%

Square, Inc., along with its subsidiaries, provides payment and point of sale solutions throughout the United States as well as internationally. Its commerce platform includes hardware and point-of sale software that allows sellers to accept payment. The company offers hardware products such as Magstripe reader which allows swiped transactions with magnetic stripe cards, Contactless reader and Chip reader which allow for Europay, MasterCard and Visa chip cards as well as Near Field Communication payments. Square Register, which integrates its point-of sale software and hardware; Square Terminal which is a mobile payments device which replaces keypad terminals and accepts numerous payment types including tap, swipe and dip as well as printing receipts. It also provides managed payment solutions. Square Point of Sale, Square Virtual Terminal, Square Appointments, Square for Retail, Square for Restaurants, Square Invoices, Square Online Store, Square Loyalty, Marketing, Gift Cards, and Square Dashboard are just a few of the software offerings. It also offers a developer platform that includes software development tools and application programming interfaces. It also offers managed payments, instant transfers, Square Card and Square Capital as well as payroll. It also offers Cash App which allows you to send, spend and store money. Weebly, on the other hand, provides customers with website hosting as well as domain registration services. Square, Inc. was established in 2009 in San Francisco, California.

NYSE ended the session with Square jumping 11.76% to $88.39 on Wednesday, after five consecutive sessions in a row of gains. NYSE jumped 0.69% to $15,267.16, after two sequential sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.

Volume

Today’s last reported volume for Square is 24507200 which is 31.66% above its average volume of 18613100.

Square’s last close was $79.09, 72.65% below its 52-week high of $289.23.

The company’s growth estimates for the present quarter and the next is a negative 71.2% and a negative 35.1%, respectively.

Square’s Revenue

Year-on-year quarterly revenue growth grew by 29.1%, now sitting on 17.66B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Square’s stock is considered to be oversold (<=20).

Square’s Stock Yearly Top and Bottom Value

Square’s stock is valued at $88.39 at 17:33 EST, way below its 52-week high of $289.23 and way higher than its 52-week low of $56.01.

Square’s Moving Average

Square’s worth is higher than its 50-day moving average of $87.32 and way below its 200-day moving average of $154.01.

More news about Square.

Most Active Losers Today

1. Citius Pharmaceuticals (CTXRW) – -58.44%

NASDAQ ended the session with Citius Pharmaceuticals sliding 58.44% to $0.02 on Wednesday while NASDAQ jumped 2.59% to $12,668.16.

Citius Pharmaceuticals’s last close was $0.02, 20.4% under its 52-week high of $0.02.

Citius Pharmaceuticals’s Stock Yearly Top and Bottom Value

Citius Pharmaceuticals’s stock is valued at $0.02 at 17:33 EST, under its 52-week high of $0.02 and way above its 52-week low of $0.02.

More news about Citius Pharmaceuticals.

2. Check-Cap Ltd. (CHEKZ) – -37.38%

NASDAQ ended the session with Check-Cap Ltd. dropping 37.38% to $0.05 on Wednesday, after five consecutive sessions in a row of losses. NASDAQ rose 2.59% to $12,668.16, after two sequential sessions in a row of losses, on what was an all-around bullish trend exchanging session today.

Check-Cap Ltd.’s last close was $0.05, 37.38% below its 52-week high of $0.08.

Check-Cap Ltd.’s Stock Yearly Top and Bottom Value

Check-Cap Ltd.’s stock is valued at $0.05 at 17:33 EST, way under its 52-week low of $0.08.

More news about Check-Cap Ltd..

3. Daseke (DSKE) – -18.95%

Daseke, Inc. offers transportation and logistic solutions, with a special focus on flatbed freight and specialty freight within the United States, Canada, Mexico. The company operates in two divisions, Flatbed Solutions or Specialized Solutions. It transports parts of aircraft, industrial equipment, steel structures, pressure vessels and wind turbine blades. The company also provides logistical planning services and warehousing. It owned 2,953 company-owned tractor and 2,099 independently-owned contractors tractors, and 11 579 trailers as of December 31, 2020. Daseke, Inc. was established in 2008 in Addison, Texas.

NASDAQ ended the session with Daseke sliding 18.95% to $6.97 on Wednesday while NASDAQ jumped 2.59% to $12,668.16.

Volume

Today’s last reported volume for Daseke is 1309130 which is 271.45% above its average volume of 352429.

Daseke’s last close was $6.97, 47.08% under its 52-week high of $13.17.

Daseke’s Sales

Daseke’s sales growth is 17.7% for the present quarter and 2% for the next. The company’s growth estimates for the ongoing quarter is a negative 20.4% and positive 23.3% for the next.

Daseke’s Revenue

Year-on-year quarterly revenue growth grew by 26.1%, now sitting on 1.64B for the twelve trailing months.

Daseke’s Stock Yearly Top and Bottom Value

Daseke’s stock is valued at $6.97 at 17:33 EST, way under its 52-week high of $13.17 and way above its 52-week low of $5.86.

Daseke’s Moving Average

Daseke’s value is higher than its 50-day moving average of $6.95 and way below its 200-day moving average of $9.15.

More news about Daseke.

4. Horizon Therapeutics (HZNP) – -18.41%

Horizon Therapeutics Public Limited Company is a biopharmaceutical firm that focuses on developing and marketing medicines to address the unmet needs of rare and rheumatic conditions in the United States. KRYSTEXA is a medication for uncontrolled gout. RAVICTI can be used as a chronic nitrogen-binding agent to manage adult and children patients. ACTIMMUNE treats chronic granulomatous disorder. BUPHENYL tablets are available for oral administration. BUPHENYL powders for intramuscular, nasogastric or stomach tube administration. QUINSAIR is a form of the antibiotic drug levofloxacin that’s intended for adult cystic fibros. PENNSAID 2% is also available. It’s indicated to treat pain from osteoarthritis of the knees. DUEXIS can be used to relieve signs and symptoms and reduce the chance of developing upper-GI Ulcers. VIMOVO, for relief of symptoms associated with OA and RA. The company has agreements to collaborate with Lupus Research, and HemoShear Therapeutics, LLC. This company used to be called Horizon Pharma Public Limited Company. In May 2019, Horizon Therapeutics Public Limited Company was adopted. Horizon Therapeutics Public Limited Company was established in 2005. It is located in Dublin, Ireland.

NASDAQ ended the session with Horizon Therapeutics falling 18.41% to $67.01 on Wednesday while NASDAQ jumped 2.59% to $12,668.16.

Volume

Today’s last reported volume for Horizon Therapeutics is 19874100 which is 908.01% above its average volume of 1971620.

Horizon Therapeutics’s last close was $82.13, 31.86% under its 52-week high of $120.54.

Horizon Therapeutics’s Sales

Horizon Therapeutics’s sales growth is 12.6% for the current quarter and 4.9% for the next. The company’s growth estimates for the present quarter and the next is a negative 16% and a negative 11.4%, respectively.

Horizon Therapeutics’s Revenue

Year-on-year quarterly revenue growth grew by 36.1%, now sitting on 3.23B for the twelve trailing months.

Horizon Therapeutics’s Stock Yearly Top and Bottom Value

Horizon Therapeutics’s stock is valued at $67.01 at 17:33 EST, way under its 52-week low of $78.40.

Horizon Therapeutics’s Moving Average

Horizon Therapeutics’s value is way under its 50-day moving average of $84.88 and way below its 200-day moving average of $98.22.

More news about Horizon Therapeutics.

5. Match Group (MTCH) – -17.63%

Match Group, Inc. offers dating products around the world. The company’s brands include Tinder and Match, Meetic as well as OkCupid, Hinge and Pairs. Dallas is the headquarters of this company.

NASDAQ ended the session with Match Group dropping 17.63% to $63.19 on Wednesday while NASDAQ rose 2.59% to $12,668.16.

Volume

Today’s last reported volume for Match Group is 17667400 which is 467.32% above its average volume of 3114150.

Match Group’s last close was $76.71, 57.85% under its 52-week high of $182.00.

The company’s growth estimates for the present quarter and the next is 13% and 37.2%, respectively.

Match Group’s Revenue

Year-on-year quarterly revenue growth grew by 23.7%, now sitting on 2.98B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Match Group’s stock is considered to be oversold (<=20).

Match Group’s Stock Yearly Top and Bottom Value

Match Group’s stock is valued at $63.19 at 17:33 EST, under its 52-week low of $63.33.

Match Group’s Moving Average

Match Group’s value is way below its 50-day moving average of $74.28 and way under its 200-day moving average of $108.71.

More news about Match Group.

6. Merrimack Pharmaceuticals (MACK) – -13.65%

NASDAQ ended the session with Merrimack Pharmaceuticals dropping 13.65% to $4.30 on Wednesday while NASDAQ rose 2.59% to $12,668.16.

Volume

Today’s last reported volume for Merrimack Pharmaceuticals is 767331 which is 5079.07% above its average volume of 14816.

Merrimack Pharmaceuticals’s last close was $4.98, 32.79% under its 52-week high of $7.41.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Merrimack Pharmaceuticals’s stock is considered to be overbought (>=80).

Merrimack Pharmaceuticals’s Stock Yearly Top and Bottom Value

Merrimack Pharmaceuticals’s stock is valued at $4.30 at 17:33 EST, way under its 52-week high of $7.41 and way above its 52-week low of $3.66.

Merrimack Pharmaceuticals’s Moving Average

Merrimack Pharmaceuticals’s worth is way under its 50-day moving average of $5.53 and way under its 200-day moving average of $5.26.

More news about Merrimack Pharmaceuticals.

7. Novo Nordisk A/S (NVO) – -12.61%

Novo Nordisk A/S is a global healthcare company that specializes in research, development and manufacture of pharmaceutical products. The company operates in two areas: Diabetes and Obesity Care and Biopharmaceuticals. Diabetes and Obesity Care provides products for insulins, GLP-1, related delivery systems and oral anti-inflammatory products. Biopharmaceuticals offers products that address haemophilia and growth disorders. Evotec AG is a strategic partner of the company. This alliance allows them to create small-molecule treatments to help patients with type 1 and 2 diabetes. It was established in Denmark in 1923. The headquarters are in Bagsvaerd.

NYSE ended the session with Novo Nordisk A/S sliding 12.61% to $100.03 on Wednesday, after two consecutive sessions in a row of losses. NYSE jumped 0.69% to $15,267.16, after two consecutive sessions in a row of losses, on what was a somewhat positive trend trading session today.

Volume

Today’s last reported volume for Novo Nordisk A/S is 5813170 which is 335.88% above its average volume of 1333640.

Novo Nordisk A/S’s last close was $114.46, 1.29% below its 52-week high of $115.95.

Novo Nordisk A/S’s Sales

Novo Nordisk A/S’s sales growth is 7.9% for the current quarter and 11.2% for the next. The company’s growth estimates for the ongoing quarter and the next is 6.9% and 12.5%, respectively.

Novo Nordisk A/S’s Revenue

Year-on-year quarterly revenue growth grew by 10.1%, now sitting on 129.91B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Novo Nordisk A/S’s stock is considered to be overbought (>=80).

Novo Nordisk A/S’s Stock Yearly Top and Bottom Value

Novo Nordisk A/S’s stock is valued at $100.03 at 17:33 EST, way under its 52-week high of $115.95 and way above its 52-week low of $66.59.

Novo Nordisk A/S’s Moving Average

Novo Nordisk A/S’s value is below its 50-day moving average of $107.59 and way above its 200-day moving average of $90.32.

More news about Novo Nordisk A/S.

8. STERIS (STE) – -9.26%

STERIS plc offers infection prevention products and procedures worldwide. The company operates through four divisions: Healthcare Products and Healthcare Specialty Services. Life Sciences is its main business. Applied Sterilization Technologies is another. Healthcare Products offers cleaning chemicals and sterilization assurance products, accessories for gastrointestinal procedures (GI), washers, sterilizers and other capital equipment necessary to operate a sterile processing unit. It also provides equipment that is directly used in an operating room such as surgical tables, lighting, management and connectivity services. The company also offers capital equipment maintenance, upgrade, repair and troubleshooting. The segment provides its services and products to ambulatory surgical centers and acute care hospitals. Healthcare Specialty Services provides managed and solutions such as endoscope and instrument repair and maintenance, custom process improvement consulting and outsourcing instrument sterile processing to hospitals and other healthcare environments. Life Sciences offers barrier and sterilization assurance products, steam- and vaporized hydroperoxide sterilizers and washer disinfectors. The Applied Sterilization Technologies section provides contract sterilization services and testing for pharmaceutical and medical device manufacturers via a network that includes approximately 50 laboratory and contract sterilization facilities. It was established in Dublin, Ireland in 1985.

NYSE ended the session with STERIS falling 9.26% to $203.65 on Wednesday while NYSE rose 0.69% to $15,267.16.

Volume

Today’s last reported volume for STERIS is 1082990 which is 121.45% above its average volume of 489029.

STERIS’s last close was $224.44, 5.44% under its 52-week high of $237.35.

The company’s growth estimates for the present quarter and the next is 23% and 13.9%, respectively.

STERIS’s Revenue

Year-on-year quarterly revenue growth grew by 44.8%, now sitting on 3.41B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

STERIS’s stock is considered to be overbought (>=80).

STERIS’s Stock Yearly Top and Bottom Value

STERIS’s stock is valued at $203.65 at 17:33 EST, way below its 52-week high of $237.35 and way higher than its 52-week low of $170.36.

STERIS’s Moving Average

STERIS’s worth is way below its 50-day moving average of $226.39 and below its 200-day moving average of $209.62.

More news about STERIS.

9. Charles River Laboratories (CRL) – -8.64%

Charles River Laboratories International, Inc. is an early-stage contract-research company that provides services for drug discovery, safety testing, and non-clinical research. The company operates in three distinct segments: Research Models and Services, Discovery and Safety Assessments (DSA) and Manufacturing Support (Manufacturing). RMS is a segment that produces and sells research models, primarily mice and rats bred for researchers. The RMS segment also offers a variety of services that assist clients with the support of research models for screening and researching non-clinical drugs candidates. These include genetically engineered models, services, insourcing solutions and diagnostic services. DSA offers in-vivo and early discovery services to identify a druggable target. This includes delivery of therapeutic and non-clinical drugs ready for safety assessment. Safety assessment services include bioanalysis, drug metabolism and toxicology. In vitro testing methods are available for non-sterile, sterile and sterile biopharmaceuticals. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines.

NYSE ended the session with Charles River Laboratories dropping 8.64% to $222.60 on Wednesday while NYSE jumped 0.69% to $15,267.16.

Volume

Today’s last reported volume for Charles River Laboratories is 1580650 which is 221.09% above its average volume of 492272.

Charles River Laboratories’s last close was $243.66, 47.05% under its 52-week high of $460.21.

Charles River Laboratories’s Sales

Charles River Laboratories’s sales growth is 26.5% for the ongoing quarter and 17.6% for the next. The company’s growth estimates for the present quarter and the next is 10.7% and 7.9%, respectively.

Charles River Laboratories’s Revenue

Year-on-year quarterly revenue growth grew by 20.5%, now sitting on 3.43B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Charles River Laboratories’s stock is considered to be oversold (<=20).

Charles River Laboratories’s Stock Yearly Top and Bottom Value

Charles River Laboratories’s stock is valued at $222.60 at 17:33 EST, under its 52-week low of $237.27.

Charles River Laboratories’s Moving Average

Charles River Laboratories’s value is way below its 50-day moving average of $393.86 and way under its 200-day moving average of $371.52.

More news about Charles River Laboratories.

10. TherapeuticsMD (TXMD) – -8.1%

TherapeuticsMD, Inc. is a United States women’s health company. The company provides IMVEXXY, a treatment for moderate-to severe dyspareunia, and BIJUVA which is a bioidentical hormonal therapy combination of 17AY-estradiol, progesterone, for moderate to severe vasomotor symptoms. TX-015HR is a transdermal patch candidate that contains progesterone and estradiol. TX-009HR is the company’s clinical product. It contains an oral progesterone/estradiol formula. The company also produces and distributes generic and branded prescription prenatal vitamins under the vitaTrue and vitaMedMD brands. It sells prescription hormone therapy drugs and prenatal vitamins to both wholesale and retail pharmacie distributors. TherapeuticsMD, Inc., is located in Boca Raton, Florida.

NASDAQ ended the session with TherapeuticsMD sliding 8.1% to $8.69 on Wednesday, after five successive sessions in a row of gains. NASDAQ jumped 2.59% to $12,668.16, after two consecutive sessions in a row of losses, on what was an all-around positive trend trading session today.

Volume

Today’s last reported volume for TherapeuticsMD is 435757 which is 71.66% below its average volume of 1537800.

TherapeuticsMD’s last close was $9.45, 82.17% below its 52-week high of $53.00.

TherapeuticsMD’s Sales

TherapeuticsMD’s sales growth is a negative 9.6% for the current quarter and 24.1% for the next. The company’s growth estimates for the present quarter and the next is 27.3% and 50%, respectively.

TherapeuticsMD’s Revenue

Year-on-year quarterly revenue growth declined by 17.3%, now sitting on 86.95M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

TherapeuticsMD’s stock is considered to be oversold (<=20).

TherapeuticsMD’s Stock Yearly Top and Bottom Value

TherapeuticsMD’s stock is valued at $8.69 at 17:33 EST, way under its 52-week high of $53.00 and way higher than its 52-week low of $1.99.

TherapeuticsMD’s Moving Average

TherapeuticsMD’s value is way above its 50-day moving average of $7.30 and way below its 200-day moving average of $17.44.

More news about TherapeuticsMD.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here